VitaVitro Biotech
VitaVitro Biotech is a Shenzhen-based medical device company founded in 2015 that manufactures cryopreservation systems, embryo culture products, and consumables for human IVF laboratories worldwide, with FDA, CE, and NMPA regulatory clearances and a portfolio anchored by Prof. Gábor Vajta's OPS vitrification technology.
- Company typePrivate
- Founded2015
- HeadquartersShenzhen, China
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What VitaVitro Biotech does
VitaVitro Biotech is a Shenzhen, China-headquartered medical device company founded in 2015 that develops, manufactures, and sells consumables and instruments for human in vitro fertilization (IVF) laboratories. Its product portfolio covers the full ART workflow, organized into cryopreservation systems (Open Pulled Straw vitrification, Vitrification and Warming Kits, Ultra-Fast Warming protocol), embryo culture systems (1-Step Culture Medium, Culture Oil, WOW Well-of-the-Well Dish, Humdish), IVF/ICSI media, sperm processing media, needles and catheters, and IVF dishes. The company's flagship Open Pulled Straw (OPS) vitrification technology, invented by Chief Scientific Advisor Prof. Gábor Vajta in 1998, is the most-cited method in mammalian embryo cryopreservation, achieving cooling/warming rates of approximately 20,000°C/min and producing the first human baby from vitrified oocytes.
The business operates a direct-to-fertility-clinic model with a single revenue stream from hardware and consumable sales. Pricing is not publicly disclosed and customers engage via the website contact form or direct outreach; VitaVitro supplements this with one-stop technical support and after-sales service, an in-house Academy, and the OPS mobile app for procedural coaching. Go-to-market is event-driven, anchored on six consecutive years of exhibition at ESHRE (2019-2024) and planned presence at ESHRE 2025 in Paris, plus regional conferences including the JSFG congress in Jordan (2024) marking Middle East entry. Manufacturing runs under GMP sanitation standards from the Shenzhen headquarters, with regulatory clearances spanning ISO 13485:2016, US QSR820, EU MDR 2017/745 (with CE certification for the cryopreservation system received in January 2025), and China NMPA, enabling sales in the United States (since 2019), Europe, China (since 2021), and select international markets.
VitaVitro Biotech firmographics
Firmographics- Name
- VitaVitro Biotech
- Legal name
- Shenzhen VitaVitro Biotech
- Website
- https://vitavitro.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- VitaVitro Biotech is a Shenzhen-based medical device company founded in 2015 that manufactures cryopreservation systems, embryo culture products, and consumables for human IVF laboratories worldwide, with FDA, CE, and NMPA regulatory clearances and a portfolio anchored by Prof. Gábor Vajta's OPS vitrification technology.
- Ownership category
- akta.pro rank
VitaVitro Biotech industry classification
Industry- Product category
- IVF Laboratory Medical Devices and Consumables
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where VitaVitro Biotech is headquartered
LocationHeadquarters
- HQ city
- Shenzhen
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
VitaVitro Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Medical Devices and Consumables for IVF: VitaVitro generates revenue through the sale of cryopreservation systems (OPS, vitrification/warming kits), embryo culture systems (culture media, culture oil, WOW dishes, Humdish), IVF/ICSI consumables (fertilization medium, gamete buffer medium, hyaluronidase), sperm processing products (sperm washing/gradient/freezing media), needles and catheters (oocyte retrieval needle, embryo transfer catheter, IUI catheter, micromanipulation pipettes), IVF dishes, and flushing buffer medium. Products are sold globally to human IVF laboratories with regulatory approvals in USA, Europe, China, and other markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | B2B medical device and consumable sales to IVF laboratories |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
VitaVitro Biotech product offering
Product offeringCore offering
Shenzhen VitaVitro Biotech manufactures and supplies medical devices and consumables for human assisted reproductive technology (ART) and IVF laboratories. Its portfolio covers cryopreservation tools (open-pulled straw vitrification devices and vitrification/warming kits), embryo culture systems (culture media and dishes), sperm processing products, and procedural consumables such as needles, catheters and flushing buffer. The products are sold globally to fertility clinics, IVF laboratories and reproductive medicine centers.
Differentiator
Problem solved
Functional benefit
Brands
- VitaVitro OPS: Open Pulled Straw vitrification system for cryopreservation of oocytes and embryos
- VitaVitro Cryopreservation System
- WOW (Well-of-the-Well) Dish
- Humdish
Products and services
- OPS Vitrification Device
- Vitrification and Warming Kits
- Embryo Culture Media and Dishes
- Sperm Processing Products
- IVF/ICSI Needles, Catheters and Flushing Buffer
Quantifiable outcome
- VitaVitro 1-step Culture Medium achieves fertilization rate of 71.2%, Day 5/6 blastocyst development rate of 58.9%, and clinical pregnancy rate of 68.89% in Chinese RCT (128 patients, 2,189 oocytes)
- +4 more outcomes
Companies that use VitaVitro Biotech
Customer profileSegments1 record
Ideal customer profiles1 record
VitaVitro Biotech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
VitaVitro Biotech partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- University Hospital Bonn (Germany)coreUniversity Hospital Bonn in Germany collaborated with VitaVitro on research demonstrating that slow-freezing ovarian tissue followed by rapid warming using VitaVitro Warming Kit achieves excellent clinical outcomes. The study showed 70% increase in primordial follicle preservation rate and 50% reduction in cell damage. Published in Reprod Biomed Online 2025.
- Dr. Lodovico ParmegianicoreDr. Lodovico Parmegiani, Scientific Director of the Reproductive Medicine Center and Nextclinics International Group, Bologna, Italy, is a key collaborator with VitaVitro. The collaboration has produced 5 co-authored publications on vitrification and safe liquid nitrogen use, with a sixth opinion paper under consideration. Dr. Parmegiani is co-author on the 2025 study demonstrating ultra-fast warming protocol efficacy (Parmegiani L et al., Reprod Biomed Online 2025).
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
VitaVitro Biotech competitors and assessment
Company assessmentEmerging players
- Fertitech: Emerging ART consumables brand distributed in select markets, offering IVF media and microtools at competitive price points. Represents the type of regional/low-cost competitor VitaVitro increasingly encounters in emerging markets.
Direct peers
- Vitrolife: Swedish-listed global leader in IVF media, consumables, and time-lapse instruments. Directly comparable product portfolio (G-series media, Rapid-i vitrification, culture dishes) and customer base (human IVF labs), making it VitaVitro's closest large-scale competitor.
- Genea Biomedx: Australia-based ART device and media specialist (Geri's time-lapse incubator, Gems culture media). Closely aligned niche focus on IVF lab workflow with overlapping media and consumables categories.
- Kitazato Corporation: Japanese ART consumables manufacturer best known for Cryotop vitrification, a direct competitor to VitaVitro's OPS and Vitrification/Warming Kit. Targets the same IVF laboratory buyers globally.
- Esco Medical: Singapore-based manufacturer of ART equipment (MIRI incubators, Mini-GTZ, time-lapse) and consumables. Closely aligned as an Asia-headquartered ART specialist targeting the same IVF lab customer segment.
- Gynemed: German IVF media and consumables manufacturer with strong EU presence. Direct competitor in culture media, sperm processing media, and cryopreservation solutions targeting European fertility clinics.
- Rocket Medical: UK-based medical device manufacturer with a dedicated ART product line (oocyte retrieval needles, embryo transfer catheters, IUI catheters). Overlaps VitaVitro's Needle & Catheter category.
Broad incumbents
- FUJIFILM Irvine Scientific: Division of FUJIFILM that manufactures cell culture media and ART consumables. Broad portfolio spans IVF, cell therapy, and industrial cell culture; competes with VitaVitro across media and cryopreservation.
- CooperSurgical (Fertility Solutions): Large diversified medical-device company with a comprehensive Fertility Solutions portfolio (Wallace catheters, media, microtools). Competes with VitaVitro across the full IVF consumables stack from a much broader corporate platform.
- Merck KGaA (Sigma-Aldrich / EmbryoMax): Global life-science giant offering EmbryoMax IVF media, cryopreservation reagents, and器械 consumables through its Sigma-Aldrich channel. Competes broadly with VitaVitro in culture media and cryo reagents.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
VitaVitro Biotech social profiles
Digital presenceVitaVitro Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
VitaVitro Biotech leadership team
Management profileNumber of profiles
Profiles3 records
VitaVitro Biotech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VitaVitro Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VitaVitro Biotech
What does VitaVitro Biotech do?
Shenzhen VitaVitro Biotech manufactures and supplies medical devices and consumables for human assisted reproductive technology (ART) and IVF laboratories. Its portfolio covers cryopreservation tools (open-pulled straw vitrification devices and vitrification/warming kits), embryo culture systems (culture media and dishes), sperm processing products, and procedural consumables such as needles, catheters and flushing buffer. The products are sold globally to fertility clinics, IVF laboratories and reproductive medicine centers.
Is VitaVitro Biotech a public or private company?
VitaVitro Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was VitaVitro Biotech founded?
VitaVitro Biotech was founded in 2015. It employs 1 to 10 people.
Where is VitaVitro Biotech based?
VitaVitro Biotech is headquartered in Shenzhen, China, in the Asia region.
How does VitaVitro Biotech make money?
One revenue line is on record: medical Devices and Consumables for IVF.
Who are VitaVitro Biotech's main competitors?
Fertitech is listed as an emerging player. Direct peers are Vitrolife, Genea Biomedx, Kitazato Corporation, Esco Medical, Gynemed and Rocket Medical. Broad incumbents are FUJIFILM Irvine Scientific, CooperSurgical (Fertility Solutions) and Merck KGaA (Sigma-Aldrich / EmbryoMax).
Does VitaVitro Biotech have an API?
No public API is recorded for VitaVitro Biotech.
What industry is VitaVitro Biotech in?
VitaVitro Biotech's product category is IVF Laboratory Medical Devices and Consumables. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 339113 and its SIC code is 3841.